Eblasakimab

• CAT Number: I040371
• CAS Number: 2445460-16-0
• Purity: ≥95%

Eblasakimab (Cat No.:I040371)is a monoclonal antibody that targets the interleukin-13 receptor alpha 1 (IL-13Rα1), blocking signaling from both IL-4 and IL-13—key cytokines involved in type 2 inflammatory responses. Developed for treating atopic dermatitis and other allergic conditions, eblasakimab aims to reduce inflammation, itching, and skin barrier dysfunction. By selectively inhibiting the IL-13Rα1 pathway, it offers a novel mechanism distinct from existing biologics. Currently in clinical trials, eblasakimab shows promise as a targeted therapy for moderate-to-severe inflammatory skin diseases.

Reference

[1]. Eblasakimab. IMGT.